search
Back to results

Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19) (OHB10cov)

Primary Purpose

Covid-19

Status
Recruiting
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)
Sponsored by
Direction Centrale du Service de Santé des Armées
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Covid-19 focused on measuring Sars-CoV2, Pneumonia, Hypoxaemic, Oxygen-dependence, Hyperbaric oxygen, Respiratory decompensation

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female, Age ≥ 18 years
  • Patient with oxygen dependence criterion: need to maintain an oxygen flow rate less than or equal to 6 liters / min to obtain: saturation by pulse oximetry (SpO2) greater than or equal to 92% or arterial gas with value PaO2 greater than 60mmHg.
  • Diagnostic confirmation of SARS-CoV-2 pneumonia

Exclusion Criteria:

  • Minor subject (age <18 years)
  • Person unable to give consent
  • Refusal to participate
  • Pregnancy
  • Participating in another research
  • Signs of respiratory decompensation requiring mechanical ventilation
  • Diagnosis of pneumonia with SARS-CoV-2 not confirmed
  • Oxygen dependence criterion exceeded i.e. need to maintain an oxygen flow rate greater than or equal to 6 liters / min to obtain: saturation by pulse oximetry (SpO2) greater than or equal to 92% or arterial gas with value of PaO2 greater than 60mmHg.
  • Inability to maintain the prolonged sitting position (at least 2 hours)
  • Subject with contraindications to HBOT

Sites / Locations

  • Hôpital d'Instruction des Armées Laveran
  • Centre Hospitalier Intercommunal de Toulon - La Seyne-sur-Mer
  • Hôpital d'Instruction des Armées Sainte-AnneRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

HBO group

Non-HBO group

Arm Description

Outcomes

Primary Outcome Measures

Time to normalize the oxygen requirement (oxygeno-dependence)
Time to normalize the oxygen requirement (oxygeno-dependence), i.e. allowing a pulse oximetry value in ambient air greater than or equal to 92% and / or arterial blood gas with a PaO2 value greater than 60mmHg in ambient air.

Secondary Outcome Measures

Days of hospitalization between the HBO group and the control group.
Number of days with oxygen need, taking into account the predictors of bad outcome
Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% values between the HBO group and the control group.
Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% between the OHB group and the control group.
Days on invasive mechanical ventilation
Days on invasive mechanical ventilation
Mortality
Mortality

Full Information

First Posted
April 9, 2020
Last Updated
February 14, 2022
Sponsor
Direction Centrale du Service de Santé des Armées
search

1. Study Identification

Unique Protocol Identification Number
NCT04344431
Brief Title
Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)
Acronym
OHB10cov
Official Title
Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 14, 2020 (Actual)
Primary Completion Date
April 2022 (Anticipated)
Study Completion Date
April 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Direction Centrale du Service de Santé des Armées

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Several patients with hypoxaemic SARS-CoV2 pneumonia were able to benefit from hyperbaric oxygen treatment (HBOT) in China. In a clinical case published in the Chinese journal of hyperbaric medicine, treatment with repeated HBO sessions prevented admission to intensive care unit with mechanical ventilation in a patient aged 69 who presented with signs of respiratory decompensation. HBOT is the most powerful oxygenation modality in the body today. HBOT can dramatically increase the amount of dissolved oxygen in the blood. HBOT not only promotes blood transport but also its tissue delivery. Furthermore, HBOT has specific immunomodulatory properties, both humoral and cellular, making it possible, for example, to reduce the intensity of the inflammatory response and to stimulate antioxidant defenses by repeating sessions. A virucidal capacity of HBOT might also be involved. HBOT is generally regarded as safe with very few adverse events. Following this feedback, it is proposed in the context of crisis management related to SARS-CoV2 to assess the value of HBO treatment of patients with CoV2 pneumonia. Indeed, it seems essential to propose therapeutic strategies to limit the risk of respiratory decompensation requiring admission to intensive care unit for patients with SARS-CoV2 pneumonia.
Detailed Description
The main objective of this study is to assess the effectiveness of HBOT in addition to normal management over the period of normalization of the oxygen requirement (oxygen dependence) in patients with SAR-CoV2 pneumonia not requiring invasive or non-invasive ventilation. It is a prospective, interventional, multicentre, controlled, randomized study. Patients admitted for SARS-CoV2 pneumonia in the Covid sector of the hospital, who have oxygen-dependence criteria will be proposed for inclusion in accordance with the inclusion and non-inclusion criteria. Randomization will be carried out to determine the allocation in two groups: an HBO group which will perform a daily session after checking for the absence of contraindication to HBO and a non-HBO control group with the same clinical criteria, but who will not benefit from HBOT sessions. In both groups, the standard continuous treatment with normobaric oxygen will be maintained.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Covid-19
Keywords
Sars-CoV2, Pneumonia, Hypoxaemic, Oxygen-dependence, Hyperbaric oxygen, Respiratory decompensation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
HBO group
Arm Type
Experimental
Arm Title
Non-HBO group
Arm Type
No Intervention
Intervention Type
Combination Product
Intervention Name(s)
Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)
Intervention Description
One session per day of HBOT in addition to the standard treatment with normobaric oxygen
Primary Outcome Measure Information:
Title
Time to normalize the oxygen requirement (oxygeno-dependence)
Description
Time to normalize the oxygen requirement (oxygeno-dependence), i.e. allowing a pulse oximetry value in ambient air greater than or equal to 92% and / or arterial blood gas with a PaO2 value greater than 60mmHg in ambient air.
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Days of hospitalization between the HBO group and the control group.
Description
Number of days with oxygen need, taking into account the predictors of bad outcome
Time Frame
1 month
Title
Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% values between the HBO group and the control group.
Description
Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% between the OHB group and the control group.
Time Frame
1 month
Title
Days on invasive mechanical ventilation
Description
Days on invasive mechanical ventilation
Time Frame
1 month
Title
Mortality
Description
Mortality
Time Frame
1 month
Other Pre-specified Outcome Measures:
Title
Number of patients requiring a permanent O2 flow rate greater than 6 liters / min with high-speed nasal mask or oxygen therapy or with invasive or non-invasive ventilation
Description
Number of patients requiring a permanent O2 flow rate greater than 6 liters / min with high-speed nasal mask or oxygen therapy or with invasive or non-invasive ventilation
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, Age ≥ 18 years Patient with oxygen dependence criterion: need to maintain an oxygen flow rate less than or equal to 6 liters / min to obtain: saturation by pulse oximetry (SpO2) greater than or equal to 92% or arterial gas with value PaO2 greater than 60mmHg. Diagnostic confirmation of SARS-CoV-2 pneumonia Exclusion Criteria: Minor subject (age <18 years) Person unable to give consent Refusal to participate Pregnancy Participating in another research Signs of respiratory decompensation requiring mechanical ventilation Diagnosis of pneumonia with SARS-CoV-2 not confirmed Oxygen dependence criterion exceeded i.e. need to maintain an oxygen flow rate greater than or equal to 6 liters / min to obtain: saturation by pulse oximetry (SpO2) greater than or equal to 92% or arterial gas with value of PaO2 greater than 60mmHg. Inability to maintain the prolonged sitting position (at least 2 hours) Subject with contraindications to HBOT
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean-Eric BLATTEAU, MD, PhD
Phone
483162189
Ext
+33
Email
jean-eric.blatteau@intradef.gouv.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Eric BLATTEAU, MD, PhD
Organizational Affiliation
Sainte-Anne military hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital d'Instruction des Armées Laveran
City
Marseille
ZIP/Postal Code
13013
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emilie JAVELLE, MD
Phone
491617504
Ext
+33
Email
emilie.javelle@intradef.gouv.fr
Facility Name
Centre Hospitalier Intercommunal de Toulon - La Seyne-sur-Mer
City
Toulon
ZIP/Postal Code
83100
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas DI STEFANO, MD
Phone
494145290
Ext
+33
Email
nicodiste@hotmail.fr
Facility Name
Hôpital d'Instruction des Armées Sainte-Anne
City
Toulon
ZIP/Postal Code
83130
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Eric BLATTEAU, MD, PhD
Phone
483162189
Ext
+33
Email
jean-eric.blatteau@intradef.gouv.fr
First Name & Middle Initial & Last Name & Degree
Jean-Eric BLATTEAU, MD, PhD
First Name & Middle Initial & Last Name & Degree
Nicolas PALEIRON, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)

We'll reach out to this number within 24 hrs